SCHEMBL8200798

SCHEMBL8200798

CN1CCN(Cc2ccc(C(=O)NN(CC(C)(C)C)c3nc(C#N)ncc3Br)cc2)CC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 6/20 0.79
CTSS P25774 5/20 0.79
CTSL P07711 4/20 0.79
CTSB P07858 1/20 0.79
HDAC6 Q9UBN7 4/20 0.46
TBK1 Q9UHD2 3/20 0.42
IKBKE Q14164 2/20 0.40
AXL P30530 1/20 0.39
BTK Q06187 1/20 0.38
KIT P10721 1/20 0.38
FLT3 P36888 1/20 0.38
F10 P00742 1/20 0.38
HDAC3 O15379 3/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC2 Q92769 3/20 0.38
HDAC8 Q9BY41 3/20 0.38
HDAC4 P56524 2/20 0.38
HDAC7 Q8WUI4 2/20 0.38
HDAC10 Q969S8 2/20 0.38
HDAC11 Q96DB2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3169501 0.95 CTSK (0.73) CTSKCTSSCTSLCTSBHDAC6
SCHEMBL8241787 0.94 CTSK (0.69) CTSKCTSSCTSLCTSBHDAC6
SCHEMBL8236641 0.91 CTSL (0.66) CTSKCTSSCTSLCTSBHDAC6
SCHEMBL5502617 0.91 CTSK (0.65) CTSKCTSSCTSLCTSBHDAC6
SCHEMBL8243086 0.91 CTSK (0.65) CTSKCTSSCTSLCTSBHDAC6
SCHEMBL8202900 0.90 CTSK (0.64) CTSKCTSSCTSLCTSBHDAC6
SCHEMBL5592896 0.88 CTSS (1.00) CTSKCTSSCTSLCTSBHDAC6
SCHEMBL5591423 0.86 CTSS (0.76) CTSKCTSSCTSLCTSBHDAC6
Trifluoroacetic Acid SCHEMBL3319243 0.85 CTSS (0.90) CTSKCTSSCTSLCTSBHDAC6
SCHEMBL8247857 0.84 CTSK (0.57) CTSKCTSSCTSLCTSBHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited , a corporation 2010-01-14 US disclosed
EP-1947091-A1 Pyrimidyl nitrile derivatives as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2008-07-23 EP disclosed
WO-2008052934-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2008-05-08 WO disclosed
EP-1918284-A1 Hydrazinopyrimidines as cysteine protease inhibitors GLAXO GROUP (GB) 2008-05-07 EP disclosed
WO-2007025774-A2 CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2007-03-08 WO disclosed
WO-2007025775-A2 CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS SERPINB1, CTRL, PRSS1 CTSK 65/4885CTSS 15/4885CTSL 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.